These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

678 related items for PubMed ID: 12673712

  • 1. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David Crawford E, Vogelzang N, Trump D, Loehrer PJ.
    Cancer; 2003 Apr 15; 97(8):1869-75. PubMed ID: 12673712
    [Abstract] [Full Text] [Related]

  • 2. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2003 Nov 15; 21(22):4083-91. PubMed ID: 14568987
    [Abstract] [Full Text] [Related]

  • 3. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.
    Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ.
    J Clin Oncol; 1998 Apr 15; 16(4):1287-93. PubMed ID: 9552027
    [Abstract] [Full Text] [Related]

  • 4. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP, Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    J Clin Oncol; 2008 Jan 20; 26(3):421-7. PubMed ID: 18202419
    [Abstract] [Full Text] [Related]

  • 5. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP.
    J Urol; 1997 Mar 20; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
    Göbel U, Bamberg M, Engert J, Gnekow AK, Haas HJ, Jürgens H, Kühl J, Lenard HG, Lumenta C, Niethammer D.
    Klin Padiatr; 1991 Mar 20; 203(4):236-45. PubMed ID: 1719267
    [Abstract] [Full Text] [Related]

  • 7. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
    Pico JL, Fadel E, Ibrahim A, Bourhis JH, Droz JP.
    Bull Cancer; 1995 Mar 20; 82 Suppl 1():56s-60s. PubMed ID: 7542945
    [Abstract] [Full Text] [Related]

  • 8. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
    Rogers PC, Olson TA, Cullen JW, Billmire DF, Marina N, Rescorla F, Davis MM, London WB, Lauer SJ, Giller RH, Cushing B, Pediatric Oncology Group 9048, Children's Cancer Group 8891.
    J Clin Oncol; 2004 Sep 01; 22(17):3563-9. PubMed ID: 15337806
    [Abstract] [Full Text] [Related]

  • 9. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
    Göbel U, Calaminus G, Teske C, Bamberg M, Bökkerink JP, Haas RJ, Holschneider AM, Janka-Schaub G, Jürgens H, Mittler U.
    Klin Padiatr; 1993 Sep 01; 205(4):231-40. PubMed ID: 7690864
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of advanced testicular cancer and toxicity of chemotherapy].
    Kawakita M, Matsuda T, Terachi T, Yoshida O.
    Hinyokika Kiyo; 1999 Nov 01; 45(11):783-6. PubMed ID: 10637744
    [Abstract] [Full Text] [Related]

  • 11. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT.
    Cancer; 2001 Apr 01; 91(7):1304-15. PubMed ID: 11283931
    [Abstract] [Full Text] [Related]

  • 12. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
    Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, deMulder P.
    J Clin Oncol; 1998 Feb 01; 16(2):692-701. PubMed ID: 9469359
    [Abstract] [Full Text] [Related]

  • 13. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
    Mardiak J, Fuchsberger P, Lakota J, Sálek T, Sycová-Milá Z, Drahokoupilová M, Baláz M, Koza I.
    Neoplasma; 2000 Feb 01; 47(4):239-43. PubMed ID: 11043829
    [Abstract] [Full Text] [Related]

  • 14. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
    Gutierrez-Delgado F, Titov DA, Tjulandin SA, Garin AM.
    Neoplasma; 1999 Feb 01; 46(3):190-5. PubMed ID: 10613596
    [Abstract] [Full Text] [Related]

  • 15. Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors.
    Attili VS, Chandra RC, Anupama G, Loknath D, Bapsy PP, Dadhich HK, Babu GK.
    J Cancer Res Ther; 2007 Feb 01; 3(3):150-2. PubMed ID: 18079577
    [Abstract] [Full Text] [Related]

  • 16. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN, Einhorn L, Mazumdar M, Bosl GJ.
    J Clin Oncol; 2007 Jan 20; 25(3):247-56. PubMed ID: 17235042
    [Abstract] [Full Text] [Related]

  • 17. The role of ifosfamide in germ cell tumors and small cell lung cancer.
    Nichols CR.
    Semin Oncol; 1995 Jun 20; 22(3 Suppl 7):13-7. PubMed ID: 7610394
    [Abstract] [Full Text] [Related]

  • 18. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A.
    Gynecol Oncol; 2004 Dec 20; 95(3):695-700. PubMed ID: 15581984
    [Abstract] [Full Text] [Related]

  • 19. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M, Miyake H, Hara I, Muramaki M, Takenaka A, Fujisawa M.
    Hinyokika Kiyo; 2007 Dec 20; 53(12):851-6. PubMed ID: 18203521
    [Abstract] [Full Text] [Related]

  • 20. [Chemotherapy of disseminated germ cell tumors].
    Kimura G, Akimoto M.
    Gan To Kagaku Ryoho; 1998 Oct 20; 25(12):1873-90. PubMed ID: 9797810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.